DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Peficitinib
Peficitinib
JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: a Focus on the Present and an Outlook on the Future
Clinical Efficacy of New JAK Inhibitors Under Development. Just More of the Same?
Clinical Review Report for Upadacitinib (Rinvoq) 2
Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
Comparison of Janus Kinase Inhibitors to Block the Type I Interferon Pathway in Human
Supplementary Materials
Fy2017 Financial Results Ended March 31, 2018
1 Clinical Significance of Janus Kinase Inhibitor Selectivity
Stembook 2018.Pdf
JAK Inhibitors in Dermatology: the Promise of a New Drug Class
Press Release
Billion Yen) Q3/FY16 Q3/FY17 Change from Fx and FCST* Ment Business Transfer
July 2017 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
Review the Rationale for Janus Kinase Inhibitors for the Treatment of Spondyloarthritis
Acute Myeloid Leukemia (AML)
Downloaded from Chemaxon (Budapest, Hungary)[115,171-183]
January 2017 TABLE of CONTENTS
Top View
Report on the Deliberation Results February 28, 2019 Pharmaceutical
April 2017 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
Phytochemicals Targeting JAK–STAT Pathways in Inflammatory Bowel Disease Models
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
Peficitinib Inhibits the Chemotactic Activity of Monocytes Via
JAK Inhibitor Poster
The Role of JAK-STAT Signaling Pathway and Its Regulators in The
Astellas Strategy
COVID-19 Treatment
THE FUTURE of JAK INHIBITORS Will JAK Inhibitors Triumph Over Persisting Regulatory Roadblocks to Offer Patients a New Treatment Option?
JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis
1518 JAK2 46216796 C28H32N4O3 472.58 1/7 4.499 Myelodysplastic Syndromes, Myelofibrosis
Kinase Inhibition in Autoimmunity and Inflammation
ATC/DDD Classification (Temporary)
A Novel JAK Inhibitor, Peficitinib, Demonstrates Potent Efficacy in a Rat
Drugs Targeting the JAK/STAT Pathway for the Treatment of Immune-Mediated Inflammatory Skin Diseases: Protocol for a Scoping Review
Janus Kinase Inhibitors and Major COVID-19 Outcomes: Time to Forget the Two Faces of Janus! a Meta-Analysis of Randomized Controlled Trials
S13054-020-03020-3.Pdf
Efficacy and Safety of Peficitinib (ASP015K) in Patients With
Q1/Fy2018 Financial Results Ended June 30, 2018
Type I Interferons in Systemic Autoimmune Diseases
Upadacitinib in Rheumatoid Arthritis: a Benefit–Risk Assessment Across
Mediated Inflammatory Diseases with Janus Kinase Inhibitors
Targeting the JAK/STAT Pathway in Solid Tumors
Rheumatology